Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPG 10101 combination therapy for the treatment of hepatitis C: A phase IB open label randomized trial of CPG 10101 alone, with interferon, ribavirin, or interferon and ribavirin in the treatment of relapsedhepatitis C Virus (HCV) subjects.

Next Previous
X
Search
Trial Profile

CPG 10101 combination therapy for the treatment of hepatitis C: A phase IB open label randomized trial of CPG 10101 alone, with interferon, ribavirin, or interferon and ribavirin in the treatment of relapsedhepatitis C Virus (HCV) subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPG 10101 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 03 Oct 2008 Official title updated, based on information from ClinicalTrials.gov.
    • 15 Apr 2007 Interim results have been presented.
    • 21 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top